![Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions - Moreau - 2017 - British Journal of Haematology - Wiley Online Library Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions - Moreau - 2017 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/57a69733-9166-458f-84d9-a2c20f335378/bjh14780-fig-0001-m.jpg)
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions - Moreau - 2017 - British Journal of Haematology - Wiley Online Library
![Update on the role of lenalidomide in patients with multiple myeloma - Sarah A. Holstein, Vera J. Suman, Philip L. McCarthy, 2018 Update on the role of lenalidomide in patients with multiple myeloma - Sarah A. Holstein, Vera J. Suman, Philip L. McCarthy, 2018](https://journals.sagepub.com/cms/10.1177/2040620718775629/asset/images/large/10.1177_2040620718775629-fig1.jpeg)
Update on the role of lenalidomide in patients with multiple myeloma - Sarah A. Holstein, Vera J. Suman, Philip L. McCarthy, 2018
![Phase I Trial of SAR650984 and Phase I/II Trial of Daratumumab for Patients with Relapsed/Refractory MM | Research To Practice Phase I Trial of SAR650984 and Phase I/II Trial of Daratumumab for Patients with Relapsed/Refractory MM | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCASH2015/6/2/Slide12.jpg)
Phase I Trial of SAR650984 and Phase I/II Trial of Daratumumab for Patients with Relapsed/Refractory MM | Research To Practice
Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Mye
![Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma](https://pbs.twimg.com/media/FbGsuakVEAggtGE.jpg)
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14) | Haematologica
![Manni Mohyuddin on Twitter: "https://t.co/S13r02vhcH So, we have overall survival results from MAIA (dara/len/dex versus len/dex for newly diagnosed myeloma) out. Some observations about post-protocol therapy and its importance in interpretation in Manni Mohyuddin on Twitter: "https://t.co/S13r02vhcH So, we have overall survival results from MAIA (dara/len/dex versus len/dex for newly diagnosed myeloma) out. Some observations about post-protocol therapy and its importance in interpretation in](https://pbs.twimg.com/media/FBqsJXhVEAQt4p4.jpg:large)
Manni Mohyuddin on Twitter: "https://t.co/S13r02vhcH So, we have overall survival results from MAIA (dara/len/dex versus len/dex for newly diagnosed myeloma) out. Some observations about post-protocol therapy and its importance in interpretation in
![PDF] New developments in the treatment of multiple myeloma – clinical utility of daratumumab | Semantic Scholar PDF] New developments in the treatment of multiple myeloma – clinical utility of daratumumab | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/bf4bcacc5272e9ba09b3f20dd9997b3a197abf7a/4-Table1-1.png)
PDF] New developments in the treatment of multiple myeloma – clinical utility of daratumumab | Semantic Scholar
![Cancers | Free Full-Text | Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises Cancers | Free Full-Text | Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises](https://www.mdpi.com/cancers/cancers-14-00113/article_deploy/html/images/cancers-14-00113-g002.png)
Cancers | Free Full-Text | Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises
![Phase I Trial of SAR650984 and Phase I/II Trial of Daratumumab for Patients with Relapsed/Refractory MM | Research To Practice Phase I Trial of SAR650984 and Phase I/II Trial of Daratumumab for Patients with Relapsed/Refractory MM | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCASH2015/6/2/Slide20.jpg)
Phase I Trial of SAR650984 and Phase I/II Trial of Daratumumab for Patients with Relapsed/Refractory MM | Research To Practice
![Cancers | Free Full-Text | Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020 Cancers | Free Full-Text | Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020](https://www.mdpi.com/cancers/cancers-12-02885/article_deploy/html/images/cancers-12-02885-g001.png)